Actively Recruiting
Phase III Study Evaluating Safety, Effectiveness, and Cellular Behavior of CT1190B in Adults with Relapsed or Refractory Large B-Cell Lymphoma
Led by UCARsgen Biotech Limited · Updated on 2026-10-01
68
Participants Needed
3
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, effectiveness, and cellular behavior of CT1190B cells in patients with relapsed or refractory large B-cell lymphoma LBCL. This Phase III clinical trial aims to find the right dose and understand how the treatment acts in the body. The study focuses on patients who have received at least two prior treatments and whose cancer has returned or not responded. Participants receive CT1190B through intravenous infusion. The trial is a single-arm, open-label study without a placebo group. The treatment period includes monitoring for up to 12 months after infusion to assess adverse events and treatment responses. Researchers will evaluate multiple outcomes including response rates, duration of response, progression-free survival, overall survival, and various cellular pharmacokinetics and immune parameters. During the study, participants will undergo regular assessments including scans to measure tumor size, laboratory tests, and monitoring of side effects. Researchers will track safety events such as treatment-related adverse events and serious adverse events for up to 12 months. Long-term outcomes like progression-free and overall survival will be followed for up to 180 months. Participants must be willing and able to complete all trial procedures and follow-up visits throughout the study duration.
CONDITIONS
Brief Title
A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Research Team
L
Lifeng Zhang Operations Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here